STUDY QUESTION: Does repeat administration of misoprostol for early pregnancy loss increase the treatment success rate?
Introduction
Early pregnancy loss is defined as a nonviable intrauterine pregnancy within the first trimester (ACOG, 2015) . The incidence of early pregnancy loss is high, reaching 10-15% of all clinically recognized pregnancies (Wilcox et al., 1988; Zinaman et al., 1996; Wang et al., 2003) . Accepted treatment options are expectant management, medical treatment or surgical evacuation (ACOG, 2015) .
Misoprostol, a prostaglandin E 1 analog, was found to be an effective treatment for patients with early pregnancy loss who wish to avoid surgical intervention. A review from the Cochrane Database of Systemic Reviews concluded that misoprostol reduces the need for surgical evacuation and shortens the time to complete expulsion, compared with placebo (Neilson et al., 2006) . Vaginal administration was superior to either oral or sublingual administration, and a dose of 800 µg was more effective than a lower dose. The American College of Obstetricians and Gynecologists (ACOG) recommends administrating an initial dose of 800 µg of misoprostol vaginally (ACOG, 2015) .
The impact of repeat doses of misoprostol is not clear (ACOG, 2009) . The ACOG states that one repeat dose may be administered no earlier than 3 h after the first dose and typically within 7 days, if there is no response to the first dose (ACOG, 2015) . Previous studies reported different treatment protocols; some researchers administered a single dose of misoprostol (Demetroulis et al., 2001; Blohm et al., 2005; Kovavisarach and Jamnansiri, 2005; Benchamanon and Phupong, 2014) , while others administered a repeat dose, as needed, after 3 h (Tang et al., 2003) , 24 h (Bagratee et al., 2004; Petersen et al., 2013) or 48 h (Zhang et al., 2005; Stockheim et al., 2006) .
In their large, randomized controlled trial, Zhang et al. (2005) demonstrated complete expulsion by Day 3 in 71% of women with first-trimester pregnancy loss after one dose of 800 µg of vaginal misoprostol. The success rate was increased to 84% by Day 8 after a second dose of 800 µg of vaginal misoprostol was administered, if needed. Yet, it is unclear whether the 13% increase in treatment success was the result of administrating a second dose of misoprostol, or the result of five more days of follow-up. Indeed, the effectiveness of misoprostol treatment also depends on the time interval to follow-up, and a higher success rate has been achieved when clinicians waited for 1-2 weeks after misoprostol treatment before judging success or failure (ACOG, 2009) . Therefore, our aim was to study whether administration of a repeat dose of misoprostol increases the treatment success rate in women with early pregnancy loss.
Materials and Methods
We performed a prospective, randomized clinical trial, in a single university affiliated tertiary medical center, between August 2015 and June 2016. The study was approved by the Institutional Review Board (Registry No. 0104-15-WOMC). The study was registered at ClinicalTrials.gov (NCT02515604).
Women diagnosed with early pregnancy loss in the gynecologic emergency room, either anembryonic gestation or embryonic death, were eligible for inclusion if pregnancy size by transvaginal sonography (TVS) was up to 12 weeks' gestation. Exclusion criteria included incomplete or septic abortion, need for urgent surgical evacuation due to heavy bleeding, hemodynamic instability, anemia (hemoglobin level below 9 g/dl), a history of bleeding disorder, failed medical abortion, multiple pregnancies and contraindication to misoprostol. The diagnosis of early pregnancy loss was made according to the recommendations published by the Society of Radiologists in Ultrasound Multispecialty Panel on Early First Trimester Diagnosis of Miscarriage and Exclusion of a Viable Intrauterine Pregnancy (Doubilet et al., 2013) .
Patients eligible for participation, were consulted about the treatment options, including medical treatment and surgical evacuation. Patients requesting medical treatment were later offered the opportunity to participate in the trial. After obtaining a written informed consent, subjects were randomly assigned to either a single-dose protocol or a repeat-dose protocol in a 1:1 ratio. A blocked randomization scheme was created using a computergenerated list of random numbers. Each block consisted of 30 participants. Treatment allocation was concealed by placing assignments in sequentially numbered opaque envelopes. After enrollment, a research assistant opened the envelope and notified the attending physician of the subject's group assignment. Consecutive inclusion was applied to avoid selection bias.
All patients were administered 800 µg of misoprostol (Cytotec, Piramal Healthcare Ltd, UK) vaginally on Day 1. Four tablets of 200 µg each were placed in the posterior fornix of the vagina by the attending physician. Patients were then asked to lie down for 30 min, after which they were discharged.
Subjects in the single-dose group were scheduled for a follow-up visit on Day 8. If complete expulsion was not achieved on Day 8 they underwent vacuum aspiration. Subjects in the repeat-dose group were scheduled for a follow-up visit on Day 4. If complete expulsion was not achieved on Day 4, they were administered a second dose of 800 µg of misoprostol vaginally and were scheduled for another follow-up visit on Day 8. Then, if complete expulsion was not achieved they underwent vacuum aspiration. Complete expulsion was defined as no gestational sac and endometrial thickness ≤15 mm on TVS. The physicians and the participants were not blinded to the study group allocation.
Vacuum aspiration was performed under general anesthesia and ultrasound guidance. The evacuated tissue was sent for pathologic examination. All patients were instructed to have another assessment by their gynecologists immediately after their next menstruation. A telephone interview was conducted on Day 45 (range 40-50) to determine whether any participant underwent additional treatment.
On Day 1, medical history, complete blood count and Rh-antigen status were obtained. All patients had a physical examination and a TVS. On each visit, physicians printed a sonographic picture of the uterine cavity on midsagittal view and added it to the patient's medical record. On their last follow-up visit on Day 4 or Day 8, after counseling about treatment success or failure, participants were asked to answer the following questions: How painful was the treatment on a scale of 1-10 (1 = no pain and 10 = worst possible pain)? Did you use over the counter (OTC) analgesics? Did you have any of the following adverse effects: nausea, vomiting, diarrhea, fever ≥38 degrees or chills? Did you have marked vaginal bleeding? Did you make an unscheduled visit to your general practitioner (GP) or to the hospital before your scheduled follow-up visit? Would you choose misoprostol treatment again (1 = definitely choose misoprostol again, 2 = probably choose misoprostol again, 3 = I don't know, 4 = probably choose surgical evacuation, 5 = definitely choose surgical evacuation)?
The primary outcome was treatment success, defined as no need for surgical intervention up to Day 8. This included emergent and elective surgical interventions. Secondary outcomes were adverse effects, pain level, OTC analgesics use, treatment acceptability and the need for late intervention as reported by the participants by telephone on Day 45.
Data were analyzed by SPSS statistical analysis software v23.0 (IBM Inc., USA). Distributions of continuous variables were assessed for normality using the Kolmogorov-Smirnov test. Normally distributed continuous outcomes were compared by Student's t-test. Continuous variables that were not normally distributed were compared by the Mann-Whitney U-test. Nominal variables were compared by the chi square test or Fisher's exact test, as appropriate. The study outcomes were compared between the participants according to their initial allocation to treatment protocol. Logistic regression analysis was used to compare the primary outcome between the study groups after adjustment for parity, which was different at recruitment. All tests were considered significant at P < 0.05.
Based on previous studies, we anticipated a success rate of~80% (Blohm et al., 2005; Zhang et al., 2005; Stockheim et al., 2006) . We initially calculated that a total of 120 patients were needed for the study to achieve statistical power. According to the study protocol, we conducted one interim analysis after 60 subjects had been recruited. No early termination occurred. Interim analysis revealed a lower success rate of 75%. Based on this rate, a sample size of 160 patients (80 in each group) was needed to detect a decrease of 30% in the primary outcome, with power of 80% and α of 0.05. Therefore, we decided to enroll 40 more patients. In addition, 20 more patients were enrolled as we anticipated that~10% of the cases would be lost to follow-up.
Results
A total of 180 patients were enrolled and randomized: 90 were assigned to the single-dose group and 90 were assigned to the repeat-dose group (Fig. 1) . Five (2.7%) participants were lost to follow-up and two participants withdrew after randomization. In the repeat-dose group, two participants were excluded on Day 4 follow-up visit: one case was found to be a twin pregnancy and one case was treated orally due to genital herpes. Overall, 87 and 84 patients were included in the final analysis in the single-dose and the repeat-dose groups, respectively.
In the single-dose group, two participants were administered a repeat dose of misoprostol upon their request. In the repeat-dose group, one participant refused to receive a repeat dose on Day 4, although endometrial thickness was measured 18 mm on TVS. The analysis of these cases, as well as cases of emergent dilation and curettage (D&C) before follow-up visit, was performed according to their initial allocation to treatment protocol. In the repeat-dose group, 40 (47.6%) patients had a complete expulsion on Day 4. Out of the 41 patients who received a second dose, 21 (51.2%) had successful complete abortion on Day 8.
There were no differences in the characteristics of the study groups at enrollment, except for parity which was higher in the single-dose group (Table I) . The treatment succeeded in 67 (77.0%) patients in the single-dose group and 64 (76.2%) patients in the repeat-dose group (relative risk (RR) 0.98; 95% CI: 0.83-1.16; P = 0.89) (Table II) . On logistic regression analysis, treatment success was still not different between the study groups after controlling for parity (adjusted odds ratio 1.17; 95% CI: 0.56-2.41; P = 0.67). Higher rate of emergent D&C due to heavy bleeding was noted in the repeat-dose group, but this difference did not reach statistical significance (P = 0.06).
A telephone interview was conducted with all participants on Day 45 (range 40-50). Only 104 (60.8%) participants had another assessment by their gynecologists, 54 in the single-dose group and 50 in the repeat-dose group. Seven (4.0%) patients underwent late interventions due to suspicion of retained products of conception (one patient in the single-dose group underwent D&C and the other six participants underwent hysteroscopy). There was no difference between the study groups regarding the need for late intervention (P = 0.71).
Adverse effects, pain scores and the acceptability of the treatment did not differ between the study groups (Table III) . Patients in the repeat-dose group reported more use of OTC analgesics. Two patients in the repeat-dose group needed blood transfusion due to severe anemia following an emergent D&C on Day 4. Both of them received a repeat dose of misoprostol. There were no hospitalizations for endometritis. All pathologic examinations of the uterine products after surgical aspiration were positive for gestational tissue.
A post hoc analysis was performed to examine an alternative definition of treatment success. Provided we had defined treatment success as no need for emergent surgical evacuation and a TVS findings of endometrial thickness ≤30 mm and no gestational sac, treatment would have succeeded in 76 (87.3%) participants in the single-dose group and 68 (80.9%) participants in the repeat-dose group (RR 0.92; 95% CI: 0.81-1.05; P = 0.25). In addition, treatment success did not differ between the study groups when applying an intention-to-treat analysis: 74.4% in the single-dose group and 71.1% in the repeat-dose group (RR 0.95; 95% CI: 0.79-1.14; P = 0.61).
Discussion
In the current study, we found that administration of a repeat dose of misoprostol on Day 4, if complete expulsion had not been achieved, did not increase the treatment success rate in patients with early pregnancy loss. Furthermore, a repeat-dose protocol was associated with more frequent use of OTC analgesics.
The success rate in the single-dose group in our study (77.0%) was similar to what was previously reported in studies that used a repeatdose protocol and a 15 mm cut-off for complete expulsion (Blohm et al., 2005; Stockheim et al., 2006) . This supports our findings that a single-dose protocol is sufficient to achieve acceptable results. Our results are in agreement with a previous study by Tang et al. (2006) , in which 180 patients with early pregnancy loss received 600 µg of misoprostol sublingually every 3 h as needed for a maximum of three doses. Patients were then randomized into two groups: subjects in Group 1 did not receive more doses of misoprostol and subjects in Group 2 received 400 µg of misoprostol sublingually daily for a further week. The success rate for complete abortion was similar in both groups. Even though Tang et al. used a different treatment protocol, their study also found no additional value to administration of repeat doses.
We are aware that in the study of Zhang et al. (2005) , success rate was slightly higher in the misoprostol group (83%). This is probably due to a different definition of treatment success. Zhang et al. used a 30 mm cut-off for complete expulsion. There is no consensus in the literature regarding the optimal definition of treatment success (ACOG, 2015) . A less conservative definition, such as endometrial thickness ≤30 mm and the absence of gestational sac is commonly used. Creinin et al. (2004) found that there is no obvious relationship between increasing endometrial thickness and the need for surgical intervention in women treated with misoprostol for early pregnancy loss. Therefore, the ACOG recommends that ultrasound examination should be used only for documenting the absence of the gestational sac (ACOG, 2015) . We used a 15 mm cut-off since this is the accepted protocol in our country. Nevertheless, we found that the presence of gestational sac on Day 8 follow-up visit did not differ between the study groups. Moreover, a post hoc analysis showed no difference in the primary outcome when using an alternative cut-off of 30 mm for endometrial thickness.
Our results suggest that a single-dose protocol is superior to a repeat-dose protocol due to comparable success rate and favorable outcomes regarding the need for analgesic drugs. Moreover, a repeatdose protocol may be associated with higher rates of emergent D&C for heavy bleeding. Naturally, a repeat-dose protocol also involves higher costs for medications, medical staff and medical facilities.
The optimal timing for administration of a second dose of misoprostol is not clear. A repeat dose may be administered no earlier than 3 h after the first dose and typically within 7 days, if there is no response to the first dose (ACOG, 2015) . In the current study, we invited the participants for a follow-up visit on Day 4 (72 h after first dose), because that was our local protocol before the beginning of the trial. The effectiveness of misoprostol treatment also depends on the time interval to follow-up, and higher success rates have been achieved when clinicians waited longer before judging success or failure (ACOG, 2009) . Therefore, we speculate that if we had performed the follow-up visit earlier, more women would have received a second dose and sustained adverse effects, with no increase in treatment success rate.
Some clinicians may question our decision to randomize the participants on Day 1, rather than Day 4. This decision had several reasons: First, we intended to study two different treatment regimens on an intention-to-treat basis. Second, inviting all patients on Day 4, would impair our ability to assess for treatment acceptability, number of days of missing work and unscheduled visits to the hospital or GP. it might increase the withdrawal rate and the cross-over rate between the study groups, since some participants might refuse not receiving a second dose in case of incomplete abortion on Day 4. To the best of our knowledge, the current study is the first to compare single and repeat administration of misoprostol in women with early pregnancy loss, in a randomized design. Furthermore, the study population was homogenous as cases of incomplete abortion were excluded. Nevertheless, several limitations must be acknowledged. First, the study was not blinded, but this may be preferred for testing treatment acceptability. Moreover, criteria for treatment success were strictly defined a priori based on objective measurements. Second, our definition of complete abortion (endometrial thickness ≤15 mm and no gestational sac) is not the common practice in all medical centers. This may weaken the generalizability of the study findings. Nevertheless, post hoc analysis showed no difference in the primary outcome when using an alternative definition. Third, follow-up time was not equal in all participants, since some had a complete expulsion on Day 4 and some underwent emergent D&C before Day 8. This, however, should not affect the primary outcome. Fourth, the follow-up visit after the first menstruation was not performed in our department. The need for another treatment was reported by phone (on Day 45) and may be subject to a recall bias. Moreover, some participants did not undergo another assessment, hence data were lacking.
In summary, in patients with early pregnancy loss, a repeat dose of misoprostol does not increase the treatment success rate, and is associated more analgesics use.
